PTO/SB/68 (04-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REQUEST FOR ACCESS TO AN APPLICATION UNDER 37 CFR 1.14(e)

In re Application of

Application Number	Filed
08/509,359	July 31, 1995
Art Unit: 1645	Examiner: Turner

Paper No. 45

Assistant Commissioner for Patents
Washington, DC 20231

1. ☐ I hereby request access under 37 CFR 1.14(e)(2) to the application file record of the above-identified ABANDONED Application, which is not within the file jacket of a pending Continued Prosecution Application (CPA) (37 CFR 1.53(d)) and is: (CHECK ONE)

☒ (A) referred to in:

United States Patent Application Publication No. _____, page _____, line_____,

United States Patent Number 6,395,960, column _____, line _____, or

an International Application which was filed on or after November 29, 2000 and which

designates the United States, WIPO Pub. No. _____, page _____, line_ ____.

☐ (B) referred to in an application that is open to public inspection as set forth in 37 CFR 1.11(b) or 1.14(e)(2)(i), i.e., Application No._____, paper No. _____, page _____, line _____.

2. ☐ I hereby request access under 37 CFR 1.14(e)(1) to an application in which the applicant has filed an authorization to lay open the complete application to the public.

Keisha T. Jenkins
Signature

3/12/03
Date

Keisha T. Jenkins
Typed or printed name

FOR PTO USE ONLY

Approved by: _____
(initials)

Unit: _____

US006395960B1

(12) **United States Patent**
St. George-Hyslop et al.

(10) **Patent No.: US 6,395,960 B1**
(45) **Date of Patent: *May 28, 2002**

(54) **TRANSGENIC MICE EXPRESSING HUMAN PRESENILIN PROTEINS**

(75) Inventors: **Peter H. St. George-Hyslop; Johanna M. Rommens; Paul E. Fraser**, all of Toronto (CA)

(73) Assignees: **The Hospital for sick Children; HSC Research and Development Limited Partnership; The Governing Council of the University of Toronto**, all of Toronto (CA)

(*) Notice: This patent issued on a continued prosecution application filed under 37 CFR 1.53(d), and is subject to the twenty year patent term provisions of 35 U.S.C. 154(a)(2).

Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **09/124,523**

(22) Filed: **Jul. 29, 1998**

Related U.S. Application Data

(60) Division of application No. 08/967,101, filed on Nov. 10, 1997, now Pat. No. 5,840,540, which is a division of application No. 08/592,541, filed on Jan. 26, 1996, now Pat. No. 5,986,054; which is a continuation-in-part of application No. 08/509,359, filed on Jul. 31, 1995, now abandoned, which is a continuation-in-part of application No. 08/496,841, filed on Jun. 28, 1995, now Pat. No. 6,210,919, which is a continuation-in-part of application No. 08/431,048, filed on Apr. 28, 1995.

(51) **Int. Cl.**[7] **A01K 67/00**; A01K 67/027; A01K 67/033

(52) **U.S. Cl.** **800/18**; 800/12; 800/13; 800/14; 800/17

(58) **Field of Search** 800/8, 12, 13, 800/14, 17, 18

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,262,332	A	11/1993	Selkoe	436/518
5,297,562	A	3/1994	Potter	128/898
5,449,604	A	9/1995	Schellenberg et al.	435/6
5,545,808	A	8/1996	Hew et al.	800/2
5,668,006	A	9/1997	Hadcock et al.	435/252

FOREIGN PATENT DOCUMENTS

CA	2054302	4/1992
CA	2071105	12/1992
CA	2096911	11/1993
WO	WO 91/19810	12/1991
WO	WO 94/00569	1/1994
WO	94/10569	5/1994
WO	94/23049	10/1994
WO	WO 97/03086	1/1997
WO	WO 97/03192	1/1997
WO	WO 97/03999	2/1997

OTHER PUBLICATIONS

Louis-Marie Houdebine, Journal of Biotechnology,"Production of pharmaceutical proteins from transgenic animals," Jan. 1994, 34, pp. 269–287.*

C.A. Kappel et al., Current Opinion in Biotechnology, "Regulating gene expression in transgenic animals," 1992, 3:548–553.*

R. M. Strojek et al., Genetic Engineering : Principles and Methods, 1988, Plenum Press, vol. 10, pp. 221–246.*

Wall, R.J. Transgenic livestock: Progress and prospects for the future. Theriogenology 45: 57–68, 1996.*

Mullins et al. Fulminant hypertension in transgenic rats harbouring the mouse Ren–2 gene. Nature 344: 541–544, Apr. 1990.*

Hammer et al. Spontaneous inflammatory disease in transgenic rats expressing HLA–B27 and human b2m: An animal model of HLA–B27–associated disorders. Cell 63: 1099–1112, Nov. 1990.*

Mullins et al. Expression of the DBA/2J Ren–2 gene in the adrenal gland of transgenic mice. EMBO J. 8: 4065–4072, 1989.*

Taurog et al. HLA–B27 in inbred and non–inbred transgenic mice. J. Immunol. 141: 4020–4023, 1988.*

Levy–Lahad et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 269: 973–977, Aug. 1995.*

Audesirk et al. Biology: Life on Earth (New York: Macmillan Publishing Company), pp. 369–401, 1986.*

Schlager et al. Spontaneous mutations and mutation rates in the house mouse. Genetics 57: 319–330, Oct. 1967.*

Wilkins, A.S. Genetic Analysis of Animal Development (New York: John Wiley & Sons), pp. 39–49, 1986.*

Yamada et al. A rat genetic linkage map and comparative maps for mouse or human homologous rat genes. Mammalian Genome 5: 63–83, 1994.*

Campbell et al. Interrelationships between energy intake and endogenous porcine growth hormone administration on the performance, body composition and protein and energy metabolism of growing pigs weighing 25 to 55 kilograms live weight. J. Anim. Sci. 6, 1988.*

Johansson et al., *J. Biol. Chem.*, 270(35):20615–20620 (1995).

(List continued on next page.)

Primary Examiner—Deborah J. R. Clark
Assistant Examiner—Anne-Marie Baker
(74) *Attorney, Agent, or Firm*—Darby & Darby

(57) **ABSTRACT**

The present invention describes the identification, isolation and cloning of two human presenilin genes, PS-1 and PS-2, mutations in which lead to Familial Alzheimer's Disease. Also identified are presenilin homologue genes in mice, *C. elegans* and *D. melanogaster*. Transcripts and products of these genes are useful in detecting and diagnosing Alzheimer's disease, developing therapeutics for treatment of Alzheimer's disease, as well as the isolation and manufacture of the protein and the constructions of transgenic animals expressing the mutant genes.

24 Claims, 12 Drawing Sheets